Objectives: Risk assessment in ICU patients using commonly used prognostic models may be influenced using different data definitions and by errors in data collection. We investigated whether a set of biomarkers (procalcitonin, MR-pro-adrenomedullin, CTpro-endothelin-1, CT-pro-arginine vasopressin, and MR-pro-atrial natriuretic peptide), alone or as a panel, could be useful in postoperative risk assessment for hospital mortality in comparison with the Acute Physiology and Chronic Health Evaluation IV score. Design: In a prospective observational cohort study, we analyzed 800 consecutive patients undergoing elective cardiac surgery. We assessed biomarker levels on admission to the ICU and every 6 hours thereafter for 24 hours. For every postoperative time point and for every biomarker, we determined the predictive value for hospital mortality and made a comparison with the Acute Physiology and Chronic Health Evaluation IV score. Setting: Intensive care of an academic referral hospital. Patients: A total of 800 consecutive patients undergoing elective cardiac surgery. Interventions: None. Measurements and Main Results: MR-pro-adrenomedullin is a good predictor of mortality (c-statistic at time point 6 hr after admission to the ICU, 0.940; 95% CI, 0.918-0.956) and performed better than the Acute Physiology and Chronic Health Evaluation IV score (c-statistic, 0.842; 95% CI, 0.811-0.868). The c-statistic did not change significantly on the time points 6, 12, and 18 hours after admission. Using a cutoff value for proadrenomedullin taken 6 hours after admission on ICU (time point 2) of 3.2 nmol/L sensitivity was 81.8% and specificity 93.9%, the positive likelihood ratio was 13.3, positive predictive value was 31.0%, and negative predictive value was 99.4%. Patients with a MR-pro-adrenomedullin above this cutoff level had an odds ratio of 68.9 (95% CI, 22.2-213.1) for not surviving their hospital stay. The other biomarkers had less predictive power. Conclusions: In elective cardiac surgery, MR-pro-adrenomedullin measured between 6 and 18 hours after admission to the ICU is a better predictor of hospital mortality in comparison with the Acute Physiology and Chronic Health Evaluation IV score. (Crit Care Med 2015; 43:373-381) 
R isk assessment of ICU patients is important for quality, scientific, and economic reasons. For risk assessment of ICU patients and quality comparison between ICUs, the Acute Physiology and Chronic Health Evaluation (APACHE) IV is widely used. It has been validated in almost all patient categories including cardiothoracic surgery patients (1) . The APACHE IV score estimates the risk of hospital mortality from actual clinical data in the first 24 hours after ICU admission, patient characteristics, chronic health evaluation, reason of admission, and diagnostic categories. The need to collect much data requires an elaborate and precise system. Furthermore, risk assessment may be greatly influenced by the used data definitions (e.g., for chronic respiratory failure or immunosuppression) or using data taken prior to ICU admission (lead time bias) (2) . It would be of great value if the simple assessment of a biomarker could aid in the risk assessment of ICU patients, improve the APACHE IV score or even replace it.
Several assays for prohormones have been developed that give information about important pathophysiologic pathways in cardiac surgery such as the inflammatory pathway (procalcitonin), the vasomotor response (MR-pro-adrenomedullin [MR-pro-ADM] and CT-pro-Endothelin-1 [CT-pro-ET1]), the neurohumoral response (CT-pro-arginine vasopressin [CT-pro-AVP]), and the cardiohumoral response (MR-proatrial natriuretic peptide [MR-pro-ANP]).
The aim of this study was to investigate whether the postoperative levels of the aforementioned biomarkers could aid in the prediction of hospital mortality, to compare their predictive value with the APACHE IV score and to determine in which timeframe the postoperative sample should be taken.
MATERIALS AND METHODS

Study Population
The study was performed at the Leiden University Medical Center, a 500-bed tertiary referral hospital. Study participants were consecutive patients undergoing elective cardiac surgery. Patients more than 18 years who could read and understand the informed consent and the study information were eligible for entrance in the study. Patients were only included after signing the informed consent. Exclusion criteria were pregnancy, active infection, emergency surgery, and participation in another study. We adhered to the Helsinki protocol and standard of good clinical practice. The study was approved by the Medical Ethical Committee (Protocol P 05.045).
Operative Procedure
Anesthesia was standardized and consisted of premedication with lorazepam (1-1.5 mg) the night and the morning before operation. Induction was achieved with propofol 1-1.5 mg/kg bolus and a remifentanyl bolus of 20-40 mcg. Anesthesia was maintained with propofol 5-6 mg/kg/hr continuously and remifentanyl 800-1,600 μg/hr continuously. Heparin was administered before the start of cardiopulmonary bypass, if applied, at a dose of 300 IU/kg bolus and subsequently at a maintenance dose adapted to maintain the activated clotting time above 400 seconds. At the end of cardiopulmonary bypass, heparin was antagonized with protamine sulfate titrated 1:1 to the initial dose of heparin (3 mg/kg). Ventilation was set at low pressure (BIPAP 10/4 cm H 2 O) and low frequency just to prevent atelectasis of the lung.
Bypass priming included 1,000 mL of a 6% HES 130/0.4 solution (Voluven, Fresenius Kabi) and 200 mL Ringers solution, 100 mL manitol 20%, 5,000 IU heparin, Cyclokapron 1,000 mg, and cefazolin 1,000 mg. After venous and arterial cannulation, bypass was commenced using a heart-lung machine (S3; Sorin Group, München, Germany), with a centrifugal blood pump (Revolution; Sorin Group, Mirandola, Italy). Oxygenation was accomplished with a hollow fiber oxygenator (Quadrox-i; Maquet, Hirrlingen, Germany). Tubing was coated with bioinert heparin-free polymers (Safeline; Maquet). Flow was laminar with rates set at 2.0-2.6 L/m 2 /min. Intermittent warm antegrade blood cardioplegia was instituted every 15-20 minutes for a period of 2 minutes at a flow of 300-450 mL/min with a pressure of 200-250 mm Hg. During bypass, the core temperature was maintained at 34-36°C. Standard surgical prophylaxis consisted of cefazoline 1 g IV, given within 1 hour to first incision.
ICU: Care
After surgery patients were transferred to the ICU for postoperative care. Care given on the ICU was standardized as much as possible. When patients were extubated and stable they were transferred to the thoracic surgery ward the next day.
Biomarker Sampling
Blood samples (9 mL; Vacuette Lithium-Heparin, Greiner Bio-One, VWR; Radnor, PA) were drawn at arrival on the ICU (T1) and every 6 hours thereafter (T2, T3, and T4) until 24 hours after admission (T5). The blood samples were immediately processed (centrifuged for 5 min with 4,000 rpm) and plasma was stored at -80°C until analysis. Sampling was stopped when the patient was discharged to the ward or needed a rethoracotomy.
Biomarkers
Specifications on the biomarkers assayed are given in detail in the references. In short, procalcitonin is considered a marker of inflammation and is raised especially in, but not limited to, invasive bacterial infection (3, 4) . Its maximum level is reached within 24 hours after the onset of infection and subsides with a half-life of about 24 hours after the inflammatory stimulus has disappeared (5, 6) . CT-pro-AVP is the C-terminal fragment of the prohormone of arginine vasopressin (or antidiuretic hormone [ADH]). AVP has a central role in water homeostasis, as antidiuretic hormone reducing free water clearance in hyperosmolar states and in volume depletion. Moreover, it acts as a potent vasoconstrictor and is released in the circulation in acute hypotension and shock because of various causes (7) . In severe chronic systolic heart failure, it is elevated in an apparent attempt to maintain an adequate effective circulating volume (8) . The prohormone is more stable when compared with the active hormone. Its concentration adequately reflects the levels of bioactive ADH and thus can be used as an alternative (9).
MR-pro-ANP is a stable fragment of the prohormone of ANP. It is produced and stored in the atria. It is secreted in low levels in healthy states and in higher levels upon atrial stretch (10) . ANP promotes natriuresis and vasodilation, thereby acting as an agent against volume overload (11, 12) . It has a strong association with N-terminal pro-B-type natriuretic peptide and in studies has been shown to predict morbidity and mortality in patients after myocardial infarction (13, 14) . The prohormone is more stable than the hormone itself and can be assayed as an alternative (12) .
MR-pro-ADM is a stable midregional fragment of the prohormone of adrenomedullin that is involved in vasomotor regulation and homeostasis (14) . Its levels are elevated in subjects with cardiac failure (15) . The prohormone is more stable than the hormone itself and can be used as an alternative (16) . CT-pro-ET1 is the C-terminal fragment of the prohormone of endothelin-1. Endothelin-1 is a potent vasoconstrictor and has an important role in the vasomotor homeostasis (17, 18) . The prohormone is more stable when compared with the hormone and can be used as an alternative (19) .
Analysis of biomarkers was done on coded samples in an external laboratory independent of the clinical team and without knowledge of outcome or access to patient data, at the courtesy of Thermo 
Patient Data
Patient characteristics were derived from their medical records. Operative data were derived from a database held by the Department of Cardiac Surgery. Perioperative and postoperative data from the operating room and ICU were derived from the Patient Data Management System used in the ICU (Metavision IMDsoft, Düsseldorf, Germany). APACHE IV scores were derived with Mediscore software (Mediscore, Itémedical, Tiel, the Netherlands) using definitions provided by the Dutch National Intensive Care Evaluation registry (23) .
Statistical Considerations
Biomarker data are not complete for all patients because of errors in the collection of samples, processing of samples, or laboratory processing. This was a complete random process. On average, 13% of the samples was missing on T1, T2, and T3; 25% was missing on T4; and 68% was missing on T5 for all biomarkers. The amount of missing data increased over time by protocol because of discharges of patients to the ward (therefore leaving the study). We decided to analyze all postoperative time points separately and only for those patients who had both an APACHE IV score and a biomarker value at that time point (Table 2 ). This means that for every time point and for every biomarker, a slightly different patient population was analyzed.
Significance of differences between outcome groups is tested using t test, Pearson chi-square or Fischer exact where appropriate. Receiver operating characteristic (ROC) analysis was done for all biomarkers on all mentioned time points, as well as for the corresponding APACHE IV score. The c statistics of biomarker and APACHE IV was compared according to the method described by DeLong et al (24) , and a p value reported. A reported value of p less than 0.05 was interpreted as a significant difference between the c-statistic of the biomarker compared with the APACHE IV score. For pro-ADM, a cutoff value was calculated with a high sensitivity and specificity based on the coordinates of the ROC curve.
All analysis was done with STATA-12 MP (StataCorp LP, College Station, TX).
RESULTS
From December 2006 to August 2010, 817 consecutive patients gave formal written consent to participate in the study. From 17 patients, accidently, no blood samples were taken. These patients were not analyzed. The median age of the 800 remaining patients was 67 years; 542 of them were men. There were 32 patients who died in hospital with a median length of stay of 17.5 days (min, 0 d; max, 89 d), three patients died during surgery. Patient characteristics are summarized in Table 1 .
The median values and (geometric) means of all biomarkers in the nonsurvivor group were higher than in the survivor group. This difference was significant for all biomarkers at all time points except for CT-pro-AVP (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/B114) Table 2 shows the discrimination between survivors and nonsurvivors as measured by the c-statistics for the biomarkers at different time points and also for the APACHE IV scores from the corresponding population. Although the APACHE IV score is always based on data from the first 24 hours after ICU admission, c-statistics may differ because populations are not identical at different time points. An ROC comparison analysis was performed, which showed that the c-statistic for MR-pro-ADM was better than the APACHE IV score on time points T2, T3, and T4, which means that a MR-pro-ADM sample taken between 6 and 18 hours after operative discriminates better between survivors and nonsurvivors than the APACHE IV score in the corresponding patient population. C-statistics for CT-pro-AVP was worse when compared with APACHE IV scores. No differences in c-statistics were found for CT-pro-ET1, procalcitonin, and MR-pro-ANP when compared with the c-statistics of the APACHE IV scores. ROC graphs of different biomarkers compared with the APACHE IV score for time point T3 are given in online supplements ( survivors and nonsurvivors by MR-pro-ADM does not change between 6 and 18 hours after operation. Multiple logistic regression analysis showed that both MR-pro-ADM and the APACHE IV score were independent predictors of hospital mortality for time points T1 to T3 when modeled together. For time points T4 and T5, the APACHE IV score was not a significant contributor in this model ( Table 3 ). The c-statistic of the model including MR-pro-ADM and the APACHE IV score at different time points was lower when compared with the c-statistic of MR-pro-ADM alone ( Table 4 ) although this finding was not statistically significant. Using a cutoff value for pro-ADM taken 6 hours after admission on ICU (time point 2) of 3.2 nmol/L sensitivity was 81.8% and specificity 93.9%, the positive likelihood ratio was 13.3 (95% CI, 9.3-19.1), the negative likelihood ratio was 0.19 (95% CI, 0.08-0.47), positive predictive value 31.0% (95% CI, 19.9%-44.7%), and negative 
DISCUSSION
The main finding of the study is that a MR-pro-ADM level, taken between 8 and 16 hours postoperative, better discriminates nonsurvivors from survivors than the APACHE IV score in patients after elective cardiac surgery. Both MR-pro-ADM and the APACHE IV score are independent predictors of mortality. However, adding the APACHE IV score to MR-pro-ADM in a prognostic model adds little to the discriminating power of MR-pro-ADM alone. ADM plays a crucial role in cardiovascular homeostasis. It is not only primarily a potent vasodilator in cardiac-overload situations but also enhances cardiac output and plays a role in the regulation of volume balance (25) . Furthermore, ADM is associated with inflammation in patients with heart failure and in human endotoxemia models (26, 27) . MR-pro-ADM has been investigated in a number of studies as a biomarker for prediction of outcome and diagnosis in different clinical settings. Morgenthaler et al (16) found a median MR-pro-ADM level of 0.56 nmol/L (interquartile range [IQR], 0.08-3.9 nmol/L) in patients with cardiovascular disease, who were planned for cardiac surgery. In patients with sepsis, they found a median MR-pro-ADM level of 3.7 (IQR, 0.72-15.4) nmol/L. Peacock et al (28) investigated several biomarkers in patients with dyspnea because of several causes in the emergency department. They found that patients who died within 14 days had a higher MR-pro-ADM level (median, 2.4; IQR, 1.6-4.7 nmol/L) than survivors (median, 1.4; IQR, 1.0-2.0 nmol/L). Travaglino et al (29) found that MR-pro-ADM alone or in combination with procalcitonin (c-statistic 0.694 and 0.790, respectively) could predict hospitalization in febrile patients admitted to the Biomarkers and  Corresponding  APACHE IV Score  T1  T2  T3  T4  T5 emergency department. In another study Travaglino et al (30) found that serial measurement of procalcitonin and MR-pro-ADM at admission and after 72 hours predicted 30-and 90-day mortality. Khan et al (31) investigated the predictive value of MR-pro-ADM in patients after myocardial infarction and found a statistical significant difference between survivors and nonsurvivors (median values, 0.71 vs 1.31 nmol/L). The reason why MR-pro-ADM levels are high in the postoperative survivor group could be because of the combined cardiovascular and inflammatory response seen in the postoperative period (32) . In the nonsurvivor group, the values of MR-pro-ADM are comparable with septic patients reflecting a more severe cardiovascular and inflammatory response. The APACHE IV score is an elaborate tool assessing severity of illness and outcome of ICU patients. It includes among others demographic data, comorbidities, laboratory values, information about cardiac function before surgery, and detailed information about the surgical procedure performed (1) . It would be of great value if a simple measurement of a biomarker in the first 24 hours after admission offered the same predictive value as the APACHE IV score. This study indeed shows that for the cardiac surgery patients, a single measurement of MR-pro-ADM sampled between 6 and 18 hours after surgery could predict mortality as least as good as the APACHE IV score. This is important because the APACHE IV score is a complex score that demands a significant workload, is time consuming, is prone to error and can, in the worst case, be manipulated (2) . MR-pro-ADM, on the other hand, can be incorporated in standard laboratory measurements and is an objective, unbiased measurement. It may be postulated that measuring MR-pro-ADM could potentially be costs saving when compared with the collection of all data needed for calculation of the APACHE IV score. However, this has never been studied yet.
A limitation of this study is the small number of patients reaching the end point mortality. Because of this, we could not construct a model with more than two or three parameters because of the danger of overfitting. Larger studies including more patients will allow building a model with more prognostic parameters. This could potentially improve the prognostic value.
Another point of consideration is that the statements in this article about MR-pro-ADM in comparison with the APACHE IV score are only valid for elective cardiac surgery patients. The results of our study cannot be extrapolated to the ICU population as a whole. Although MR-pro-ADM is a predictor of mortality in other ICU patient categories (33, 34) , these studies did not make a comparison with the APACHE IV score.
In this study, the population was predominantly men (68%), which is different from the population from which the APACHE score was constructed (54.2% men) (1) and could lead to potential bias.
The odds ratio of dying in hospital for patients with a MR-pro-ADM level above 3.2 nmol/L 6 hours after admission should be interpreted with great caution because of the low number of cases and therefore wide CIs. Moreover, although the odds ratio for mortality associated with a MR-pro-ADM T1  T2  T3  T4  T5 MR-pro-ADM higher than 3.2 nmol/L, was very high, i.e., 68.9 (95% CI, 22.2-213.1), the positive predictive value for mortality was only 31%. The cutoff value of 3.2 nmol/L was arbitrarily chosen on the basis of the ROC curve in this study. We cannot rule out that other cutoff values would be more appropriate in other populations. To confirm our findings, additional studies should, ideally, be conducted in multiple centers with more patients and patient categories included.
C-Statistic of MR-Pro-Adrenomedullin Compared With C-Statistic of Acute Physiology and Chronic Health Evaluation IV and C-Statistic of Combined Model With MR-Pro-Adrenomedullin and Acute Physiology and Chronic Health Evaluation IV
MR-pro-ADM and Models
CONCLUSIONS
This is, to our knowledge, the first study, which addresses the question whether a biomarker can help in postoperative risk stratification in cardiac surgery patients in comparison with the APACHE IV score. MR-pro-ADM levels taken between 6 and 18 hours postoperatively in elective cardiac surgery patients predict hospital mortality well and even better than the APACHE IV score. Additional studies should be conducted to confirm these results and to address the question whether MR-pro-ADM also predicts hospital mortality in other ICU populations in comparison with the APACHE IV score. Other studies should address the question whether MR-pro-ADM could be incorporated in risk assessment scores and other quality measurements for ICU care to detect high-risk patients and to improve quality of care and survival of patients.
